{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-027724","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.843616+00:00","generated_at":"2026-06-11T15:33:39.301897+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biofrontera Q2 revenue up 31% to $5.8M, net loss widens to $9.8M; cash $4.5M","bullets":["Revenue $5.8M (+31% YoY); net loss $9.8M ($7.23/share) vs $0.9M loss in Q2 2022.","Cash $4.5M, down from $17.2M at Dec 31, 2022; equity investment in Biofrontera AG $5.9M.","Founder Hermann Luebbert named CEO, continues as Executive Chairman.","Affirms FY 2023 revenue growth at least 25%; expects cash flow positive within ~1.5 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-027724","json":"https://secwatch.observer/filing/0001493152-23-027724.json","markdown":"https://secwatch.observer/filing/0001493152-23-027724.md","text":"https://secwatch.observer/filing/0001493152-23-027724.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223027724/0001493152-23-027724-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223027724/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T15:33:39.301897+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"18ed31c4a3efe35409cb3e33057804936b27c509","claim":"Biofrontera Inc. reported the six months ended June 30, 2023 results: revenue $14.6 million, net income $17.3 million, EPS $(12.73) per share. Guidance reaffirmed.","evidence_excerpt":"interest income and expense, income taxes, depreciation and amortization, and certain other non-recurring or non-cash items. Six Month Financial Results Total revenues were $14.6 million for the first half of 2023 compared with $14.2 million for the first half of 2022. The increase was primarily driven by a higher volume of Ameluz sales due to the sales team","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223027724/0001493152-23-027724-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six months ended June 30, 2023"},{"label":"Revenue","value":"$14.6 million"},{"label":"Net income","value":"$17.3 million"},{"label":"EPS","value":"$(12.73) per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"3be3b3ab1e5d5c3b5bcba3c5d26a7690c7bd35f6","claim":"Biofrontera Inc. reported the three months ended June 30, 2023 results: revenue $5.8 million, net income $9.8 million, EPS $(7.23) per share. Guidance reaffirmed.","evidence_excerpt":"and six months ended June 30, 2023 and provided a business update. Highlights from the second quarter of 2023 and subsequent weeks included the following: ● Total revenues were $5.8 million, an increase of 31% from the comparable prior-year period ● Cash and cash equivalents were $4.5 million as of June 30, 2023, compared with $17.2 million as of December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223027724/0001493152-23-027724-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended June 30, 2023"},{"label":"Revenue","value":"$5.8 million"},{"label":"Net income","value":"$9.8 million"},{"label":"EPS","value":"$(7.23) per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}